chevron_leftBack
As of 24 April 2025, Newron Pharmaceuticals S.p.A. has a market cap of $176.41M USD, ranking #18239 globally and #149 in Italy. It ranks #1816 in the Healthcare sector, and #524 in the Biotechnology industry.
Key Stats
Market Cap
$176.41MUSD
145.7M CHF
Enterprise Value
$222.58MUSD
183.83M CHF
Revenue (TTM)
$58.38MUSD
48.21M CHF
EBITDA (TTM)
$29.76MUSD
24.58M CHF
Net Income (TTM)
$18.0MUSD
14.86M CHF
EBITDA Margin
51%
Profit Margin
31%
PE Ratio
10.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Stefan Weber
open_in_new
Employees
22
Founded
1999
Website
newron.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.6% | 14% | -13% | -22% | -19% | 1.7% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NWRN
Newron Pharmaceuticals SpA
ISIN: IT0004147952
Shares Out.:
Shares Outstanding:
19.959M1
Shares Float:
17.743M2
|
7.18 CHF | |
|
0QOI
Newron Pharmaceuticals SpA
ISIN: IT0004147952
|
6.57 CHF | |
|
NP5
Newron Pharmaceuticals SpA
ISIN: IT0004147952
|
7.30 EUR | |
|
NP5
Newron Pharmaceuticals SpA
ISIN: IT0004147952
|
7.54 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
